The virus was found in a total of 28 out of 644 patients with severe brain infections in the study, corresponding to around 4 per cent, but not in any of the 122 patients with non-infectious brain disorders that were tested.
Infections of the brain and central nervous system are often fatal, and patients who survive – often young children and young adults – are left severely disabled. Brain infections can be caused by a range of bacterial, parasitic, fungal and viral agents; however, doctors fail to find the cause of the infection in more than half of all cases, despite extensive diagnostic efforts. Not knowing the causes of these brain infections makes public health and treatment interventions impossible.
Researchers at the Oxford University Clinical Research Unit, the Wellcome Trust South East Asia Major Overseas Programme and the Academic Medical Center at the University of Amsterdam identified the virus, tentatively named CyCV-VN, in the fluid around the brain of two patients with brain infections of unknown cause. The virus was subsequently detected in an additional 26 out of 642 patients with brain infections of known and unknown causes.
Using next-generation gene sequencing techniques, the team sequenced the entire genetic material of the virus, confirming that it represents a new species that has not been isolated before. They found that it belongs to a family of viruses called the Circoviridae, which have previously only been associated with disease in animals, including birds and pigs.
Dr Rogier van Doorn, Head of Emerging Infections at the Wellcome Trust Vietnam Research Programme and Oxford University Clinical Research Unit Hospital for Tropical Diseases in Vietnam, explains: “We don’t yet know whether this virus is responsible for causing the serious brain infections we see in these patients, but finding an infectious agent like this in a normally sterile environment like the fluid around the brain is extremely important. We need to understand the potential threat of this virus to human and animal health.”
The researchers were not able to detect CyCV-VN in blood samples from the patients, but it was present in 8 out of 188 faecal samples from healthy children. The virus was also detected in more than half of faecal samples from chickens and pigs taken from the local area of one of the patients from whom the virus was initially isolated, which may suggest an animal source of infection.
Dr Le Van Tan, Oxford University Clinical Research Unit, Wellcome Trust Major Overseas Programme, said: “The evidence so far seems to suggest that CyCV-VN may have crossed into humans from animals, another example of a potential zoonotic infection. However, detecting the virus in human samples is not in itself sufficient evidence to prove that the virus is causing disease, particularly since the virus could also be detected in patients with other known viral or bacterial causes of brain infection.
“While detection of this virus in the fluid around the brain is certainly remarkable, it could still be that it doesn’t cause any harm. Clearly, we need to do more work to understand the role this virus may play in these severe infections.”
The researchers are currently trying to grow the virus in the laboratory using cell culture techniques to develop a blood assay to test for antibody responses in patient samples, which would indicate that the patients had mounted an immune response against the virus. Such a test could also be used to study how many people in the population have been exposed to CyCV-VN without showing symptoms of disease.
The team are collaborating with scientists across South-east Asia and in the Netherlands to determine whether CyCV-VN can be detected in patient samples from other countries and better understand its geographical distribution.
Professor Menno de Jong, head of the Department of Medical Microbiology of the Academic Medical Centre in Amsterdam, said: “Our research shows the importance of continuing efforts to find novel causes of important infectious diseases and the strength of current technology in aid of these efforts.”
The study, funded by the Wellcome Trust, the European Union and the Li Ka Shing Foundation-University of Oxford Global Health Program, was published today in the journal ‘mBio’ from the American Society for Microbiology.
Image: Positron emission tomograph of brain. Credit: Wellcome Images.
Senior Media Officer, Wellcome Trust
T +44 20 7611 7262
E [email protected]
Notes to editors
Tan LV et al. Identification of a new cyclovirus in cerebrospinal fluid of patients with acute central nervous system infections. mBio 2013.
About the Wellcome Trust
The Wellcome Trust is a global charitable foundation dedicated to achieving extraordinary improvements in human and animal health. It supports the brightest minds in biomedical research and the medical humanities. The Trust’s breadth of support includes public engagement, education and the application of research to improve health. It is independent of both political and commercial interests.
About the Wellcome Trust Oxford University Clinical Research Unit
The Oxford University Clinical Research Unit (OUCRU-VN) in Vietnam was established in 1991 with support from the Hospital for Tropical Diseases (HTD) in Ho Chi Minh City, the Health Services of Ho Chi Minh City and the Wellcome Trust. OUCRU-VN has developed strong links not only with HTD but also with other hospitals in Ho Chi Minh City, Hanoi and other regions of Vietnam.
About the University of Oxford’s Medical Sciences Division
The University of Oxford’s Medical Sciences Division is one of the largest biomedical research centres in Europe, with over 2,500 people involved in research and more than 2,800 students. The University is rated the best in the world for medicine, and it is home to the UK’s top-ranked medical school.
From the genetic and molecular basis of disease to the latest advances in neuroscience, Oxford is at the forefront of medical research. It has one of the largest clinical trial portfolios in the UK and great expertise in taking discoveries from the lab into the clinic. Partnerships with the local NHS Trusts enable patients to benefit from close links between medical research and healthcare delivery.
A great strength of Oxford medicine is its long-standing network of clinical research units in Asia and Africa, enabling world-leading research on the most pressing global health challenges such as malaria, TB, HIV/AIDS and flu. Oxford is also renowned for its large-scale studies which examine the role of factors such as smoking, alcohol and diet on cancer, heart disease and other conditions.